Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: dates

The MVA viral platform for the treatment of cancer and chronic infectious diseases: Clinical experience from four randomized controlled phase II studies

Poster MVA VIRAL PLATFORM-AACR 2015-JML Jean-Marc Limacher, et al. AACR Annual Meeting, Philadelphia, PA, USA, 18-22 April 2015, Abst. 2498. Download the poster here Poster Presentation

Published 21 April 2015
Categorized as -others, 2015, Publication, TG4010

Agreement with FDA Announced for Special Protocol Assessment for Upcoming Phase 3 Pexa-Vec Trial in Advanced Liver Cancer

20150416 SPA release version EN clean

Published 16 April 2015
Categorized as 2015, Pexa-Vec, Press release

Transgene Reports 2014 Financial Results and Outlines Promising Clinical Pipeline (webcast)

20150324 FY results 2014 full release_ENG FINAL

Published 24 March 2015
Categorized as 2015, Press release

Transgene Announces New Pre-Clinical Data with TG4010 in Combination with Immune Checkpoint Inhibitors and TG3003 (humanized mAb anti-CD115) to be Presented at AACR

18032015_AACR 2015 curtain raiser_EN

Published 19 March 2015
Categorized as 2015, Press release, TG3003, TG4010

Viral hepatitis: HBV cure—can we pin our hopes on immunotherapy ?

Hung-Chih Yang, et al. Nature Reviews Gastroenterology & Hepatology (2015) doi:10.1038/nrgastro.2015.8 – Download the article Publication

Published 5 February 2015
Categorized as -others, 2015, Publication, TG1050

Transgene Announces Financial Calendar for 2015

20150107 PR 2015 financial calendar_EN_ver 1

Published 8 January 2015
Categorized as 2015, Press release

TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice.

Martin P, Dubois, et al. Gut. 2014 Nov 26, doi: 10.1136/gutjnl-2014-308041 – Download the article Publication

Published 26 November 2014
Categorized as -others, 2014, Publication, TG1050

TG4010 Immunotherapy Combined with First-line Therapy in Advanced Non- Small Cell Lung Cancer (NSCLC). Phase 2b Results of the TIME Study

Elisabeth Quoix, et al. Journal for Immunotherapy of Cancer, 2014, 2 (suppl. 3), O12 – Download the article Publication

Published 6 November 2014
Categorized as -others, 2014, Publication, TG4010

Transgene Announces Third Quarter 2014 Financial Results

266_en

Published 21 October 2014
Categorized as 2014, Press release

TIME: A Phase 2b/3 Evaluating TG4010 in Combination with First-line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC). Phase 2b results.

ESMO 2014-Poster TG4010 TIME Ph 2b Elisabeth Quoix, et al. ESMO 2014 Congress, Madrid, Spain, 26-30 September 2014, Abst. 5152 Download the poster here Poster Presentation

Published 30 September 2014
Categorized as -others, 2014, Publication, TG4010

Posts pagination

Newer posts Page 1 … Page 45 … Page 47 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu